Clinical Trial Update: A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating adverse events, changes in disease activity, tolerability, and pharmacokinetics of intravenous ABBV-438 in adults with multiple …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ABBV-438

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING